OPRX vs HCAT

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 02, 2026

OPRX

35.8
AI Score
VS
HCAT Wins

HCAT

44.0
AI Score

Investment Advisor Scores

OPRX

36score
Recommendation
SELL

HCAT

44score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric OPRX HCAT Winner
Revenue 40.35M 141.24M HCAT
Net Income -1.20M -151.56M OPRX
Net Margin -3.0% -107.3% OPRX
Operating Income 308,000 -142.96M OPRX
ROE -0.9% -150.3% OPRX
ROA -0.7% -42.3% OPRX
Total Assets 164.32M 358.60M HCAT
Cash 24.10M 60.59M HCAT
Debt/Equity 0.15 1.52 OPRX
Current Ratio 5.58 2.70 OPRX
Free Cash Flow 8.09M 18.10M HCAT

Relative Price Performance (Last 90 Days)

OPRX 1M: +13.7% · 3M: +32.8% HCAT 1M: -17.7% · 3M: -19.6%

Current Technical Phase

OPRX

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (7.3% over 20 days), RSI 56

RSI (14): 56.3 · Price: $9.35

HCAT

Markdown
Sell / avoid

Price below a falling SMA50 (slope -2.9%), weak momentum, RSI 38

RSI (14): 38.2 · Price: $1.44

Fundamentals Snapshot

Metric OPRX HCAT
Market Cap — —
Forward P/E 9.0 -36.0
Trailing P/E 39.5 —
Revenue (TTM) — —
Revenue Growth -0.3% -0.3%
Gross Margin 0.7% 0.5%
Operating Margin 0.0% -0.2%
EPS 0.24 -2.80
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, HCAT is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.